Science is for sale: Five Times Industry Bought the Science

ONE WILD WORLD — NEWSLETTER

Issue #032   ·   Science for Sale   ·   June 2026

Five Times Industry Bought the Science

^{A prestigious journal. A respected scientist's name on the paper. A conclusion that just happens to protect a billion-dollar product. The playbook is always the same, and it has killed an astonishing number of people. Here are five times a company paid to manufacture the science} — and got away with it for years.

There's a particular trick that powerful industries have used over and over for the past seventy years, and once you've seen it you can't stop seeing it. It works like this: a product is making someone enormous amounts of money. Evidence starts to appear that the product is harmful. Instead of fixing the product, the company funds research — real research, in real journals, with real scientists' names attached — designed to muddy the water. The goal isn't to prove the product is safe. The goal is just to create enough doubt that regulation stalls and sales continue.

The strategy has a name now: manufacturing doubt. It was pioneered by one industry and copied by all the others. What follows are five of the clearest, best-documented examples — each one confirmed not by speculation but by internal documents the companies were eventually forced to hand over in court.

1  Tobacco Wrote the Playbook

On 14 December 1953, the heads of America's biggest tobacco companies met at the Plaza Hotel in New York. The problem: researchers had just shown that cigarette tar painted on mice caused fatal cancers, and the press was running with it. The solution they agreed on was not to make a safer cigarette. It was to hire a PR firm.

The result was the Tobacco Industry Research Committee and, in January 1954, a full-page advertisement called 'A Frank Statement to Cigarette Smokers' that ran in over 400 newspapers and reached an estimated 43 million people. It promised that the industry would fund impartial research into smoking and health. Over the next forty years, the industry poured more than $300 million into research — but the committee rarely funded anything that might confirm the smoking-cancer link. Its actual job was to find friendly scientists, generate doubt, and present a settled scientific question as an open controversy.

2  One Man Owned All the Lead Data

When tetraethyl lead was added to petrol in the 1920s to stop engine knock, workers at the manufacturing plants began dying — convulsing, hallucinating, and in several cases dropping dead. General Motors, Standard Oil, and DuPont, who jointly produced it, had a problem. Their solution was to hire a physiologist named Robert Kehoe.

Kehoe became the industry's scientific authority on lead — and because almost all research funding on leaded petrol flowed through him, he held what one account called an 'almost complete monopoly' on the data for half a century. His position, which became known as the Kehoe Rule, was that lead should be presumed safe until critics could prove otherwise to an impossible standard. For decades, his lab was effectively the only source of information, and he used it to insist that ambient lead was normal and harmless.

It took a geochemist named Clair Patterson — who stumbled onto the problem while measuring the age of the Earth — to break the monopoly. When Patterson published evidence that modern humans carried hundreds of times more lead than pre-industrial people, the industry struck back: the American Petroleum Institute cancelled his research contract, and Ethyl reportedly pressured Caltech to fire him, even offering to endow a university chair if he was 'sent packing.'

3  Merck Deleted the Heart Attacks

Vioxx was a painkiller, approved by the FDA in 1999 and marketed by Merck as a gentler alternative to older anti-inflammatories. Around 80 million people worldwide took it. The problem was that it sharply increased the risk of heart attacks and strokes — and Merck's own data showed it.

When Merck published the key VIGOR study in the New England Journal of Medicine in 2000, the presentation was artful. It emphasised that a comparison drug, naproxen, appeared to cut heart attacks by 80% — framing Vioxx's danger as naproxen's benefit. Years later, the journal's editors discovered that data on three additional heart attacks had been deleted from the manuscript before submission. The journal said it had been 'hoodwinked.' Separately, researchers documented that in 16 of 20 Vioxx clinical-trial papers, the initial draft was written by a Merck employee, with an outside academic later added as 'first author' to lend the appearance of independence — a practice called ghostwriting.

4  The Five-Sentence Letter That Started an Epidemic

In January 1980, the New England Journal of Medicine published a short letter to the editor from two researchers, Jane Porter and Hershel Jick. It noted that among hospitalised patients given narcotics under close supervision, addiction was rare. It was five sentences long. It contained no study, no methodology, no data table. It was an observation about inpatients in a controlled hospital setting.

It sat ignored for fifteen years. Then Purdue Pharma launched OxyContin, and the letter found a second life. Purdue's marketing cited it — stripped of its hospital-only context — as evidence that 'the rate of addiction for patients treated by doctors is much less than 1 per cent.' The claim appeared in brochures, in a TV commercial, and in the training of a sales force that more than doubled in size. The actual addiction rate for opioid pain treatment, the CDC has said, runs as high as 26 per cent.

5  Lead Paint Had a Mascot

While leaded petrol was poisoning the air, leaded paint was poisoning homes — and the lead industry knew. As early as the 1900s, lead poisoning in children was documented in medical literature. The Lead Industries Association, the trade body, was aware of the hazard to children by the 1930s. Their response was not to stop selling it.

Instead, the industry marketed lead paint aggressively, including directly to families and children. The Dutch Boy paint brand used a cheerful child mascot. Advertisements promoted lead paint for nurseries and children's rooms, emphasising how washable and bright it was. Internally, the industry funded and promoted research minimising the dangers and shifting blame onto 'uneducated' parents and children who ate paint chips — framing a product-safety crisis as a problem of personal responsibility.

The US didn't ban lead paint for residential use until 1978. Decades of children had already been exposed, with effects — lowered IQ, behavioural problems, developmental damage — that are permanent and irreversible.

The thread running through all five is not that the products were dangerous — plenty of useful things are dangerous. It's that in each case the company knew, had the evidence in hand, and chose to spend money on doubt rather than on safety. The science wasn't absent. It was bought, buried, or both.

And the playbook still works, because it exploits something real: actual science is full of genuine uncertainty, and a well-funded campaign can always make a settled question look open to a non-expert. The defence isn't to distrust all science. It's to ask a simple question whenever a comforting study appears at a convenient moment — who paid for this?

In every one of these cases, the answer to 'who paid for this?' was the company with the most to lose.

The doubt was the product.

SOURCES

Oreskes, N. and Conway, E.M. — Merchants of Doubt: How a Handful of Scientists Obscured the Truth on Issues from Tobacco Smoke to Global Warming. Bloomsbury (2010). The definitive account of the 'manufacturing doubt' playbook.

Tobacco Industry Research Committee — 'A Frank Statement to Cigarette Smokers' (January 1954). Reproduced and analysed at tobaccotactics.org and in US v. Philip Morris court records.

Brandt, A. — The Cigarette Century (2007). On the tobacco industry's research strategy.

Kehoe, R.A. and the Kehoe Rule — see Wikipedia 'Robert A. Kehoe' and Rosner & Markowitz, Deceit and Denial: The Deadly Politics of Industrial Pollution (2002).

Patterson, C.C. — landmark lead contamination research (1965); Senate testimony (1966). See Wikipedia 'Clair Patterson.'

Ross, J.S. et al. — 'Guest Authorship and Ghostwriting in Publications Related to Rofecoxib (Vioxx).' JAMA (2008). DOI: 10.1001/jama.299.15.1800

NEJM Editors (Drazen, J.M., Curfman, G.D. et al.) — 'Expression of Concern: Bombardier et al., VIGOR study.' New England Journal of Medicine (2005).

Graham, D. — Testimony before US Senate Finance Committee on Vioxx (2004). On estimated excess deaths.

Porter, J. and Jick, H. — 'Addiction Rare in Patients Treated with Narcotics.' New England Journal of Medicine letter (1980). NEJM editor's note added 2017.

Van Zee, A. — 'The Promotion and Marketing of OxyContin.' American Journal of Public Health (2009).

Quinones, S. — Dreamland: The True Tale of America's Opiate Epidemic (2015).

Washington State Attorney General — complaint against Purdue Pharma (2017). On the <1% addiction claim and the 26% CDC figure.

Rosner, D. and Markowitz, G. — Lead Wars: The Politics of Science and the Fate of America's Children (2013). On the lead paint industry's conduct.

California v. ConAgra, NL Industries, Sherwin-Williams — lead paint public nuisance litigation, judgment (2018).

Union of Concerned Scientists — 'The Disinformation Playbook' (ucs.org). Case summaries on tobacco, Vioxx, and lead.

ONE MORE THING

Like having your assumptions quietly taken apart? There’s a second newsletter from the same desk. iPrompt is a free weekly AI intelligence brief — the AI news, tools and prompts that actually matter, with the fluff cut out.

Two editions a week, five minutes each.

Subscribe free at iprompt.com →